Copy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells
Background The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP). Objective To investigate the association between CNVs and structural forms on...
Saved in:
Published in | Movement disorders Vol. 40; no. 5; pp. 950 - 961 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.05.2025
|
Subjects | |
Online Access | Get full text |
ISSN | 0885-3185 1531-8257 1531-8257 |
DOI | 10.1002/mds.30150 |
Cover
Summary: | Background
The 17q21.31 region with various structural forms characterized by the H1/H2 haplotypes and three large copy number variations (CNVs) represents the strongest risk locus in progressive supranuclear palsy (PSP).
Objective
To investigate the association between CNVs and structural forms on 17q.21.31 with the risk of PSP.
Methods
Utilizing whole genome sequencing data from 1684 PSP cases and 2392 controls, the three large CNVs (α, β, and γ) and structural forms within 17q21.31 were identified and analyzed for their association with PSP.
Results
We found that the copy number of γ was associated with increased PSP risk (odds ratio [OR] = 1.10, P = 0.0018). From H1β1γ1 (OR = 1.21) and H1β2γ1 (OR = 1.24) to H1β1γ4 (OR = 1.57), structural forms of H1 with additional copies of γ displayed a higher risk for PSP. The frequency of the risk sub‐haplotype H1c rises from 1% in individuals with two γ copies to 88% in those with eight copies. Additionally, γ duplication up‐regulates expression of ARL17B, LRRC37A/LRRC37A2, and NSFP1, while down‐regulating KANSL1. Single‐nucleus RNA‐seq of the dorsolateral prefrontal cortex analysis reveals γ duplication primarily up‐regulates LRRC37A/LRRC37A2 in neuronal cells.
Conclusions
The copy number of γ is associated with the risk of PSP after adjusting for H1/H2, indicating that the complex structure at 17q21.31 is an important consideration when evaluating the genetic risk of PSP. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
---|---|
Bibliography: | L.M.‐P. received income from Biogen as a consultant in 2022. G.R. has been employed by Roche (Hoffmann‐La Roche, Basel, Switzerland) since 2021. Her affiliation while completing her contribution to this manuscript was German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. T.G.B. is a consultant for Aprinoia Therapeutics and a scientific advisor and stock option holder for Vivid Genomics. H.R.M. is employed by University College London (UCL). In the last 12 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics, and Amylyx; and lecture fees/honoraria from BMJ, Kyowa Kirin, and the Movement Disorder Society. H.R.M. is a co‐applicant on a patent application related to C9ORF72: Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). G.C. is currently an employee of Regeneron Pharmaceuticals. A.M.G. serves on the scientific advisory board for Genentech and Muna Therapeutics. This work was supported by National Institutes of Health (NIH) 5UG3NS104095, the Rainwater Charitable Foundation, and CurePSP. H.W. and P.‐L.C. are supported by RF1‐AG074328, P30‐AG072979, U54‐AG052427, and U24‐AG041689. T.S.C. is supported by NIH K08AG065519 and the Larry L. Hillblom Foundation 2021‐A‐005‐SUP. Y.‐Q.S., A.T., and J.‐Y.T. are supported by RF1‐AG074328. K.F. was supported by CurePSP 685‐2023‐06‐Pathway and K01 AG070326. M.G. is supported by P30 AG066511. B.F.G. and K.L.N. are supported by P30 AG072976 and R01 AG080001. T.G.B. and G.E.S. are supported by U24 NS072026, P30 AG019610, P30AG072980, the State of Arizona, and The Michael J. Fox Foundation for Parkinson's Research. I.L. is supported by 2R01AG038791‐06A, U01NS100610, R25NS098999, U19 AG063911‐1, and 1R21NS114764‐01A1. O.A.R. is supported by U54 NS100693. D.G. is supported by P30AG062429. A.L.B. is supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. B.L.M. is supported by P01 AG019724, R01 AG057234, and P0544014. V.M.V.D. is supported by P01‐AG‐066597 and P01‐AG‐017586. H.R.M. is supported by CurePSP, PSPA, MRC, and The Michael J. Fox Foundation. R.D.S. is supported by CurePSP, PSPA, and Reta Lila Weston Trust. J.F.C. is supported by R01 AG054008, R01 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable Foundation/Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane Martin. A.M.G. is supported by the Tau Consortium and U54‐NS123746. Y.C. is supported by CIBERNED (CB06/05/0018‐ISCIII), Maria de Maeztu Excellence Center, CERCA Generalitat de Catalunya. Y.Y.L. is supported by U54‐AG052427 and U24‐AG041689. L.‐S.W. is supported by U01AG032984, U54AG052427, and U24AG041689. G.U.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy‐ID 390857198); Deutsche Forschungsgemeinschaft (DFG, HO2402/18‐1 MSAomics); German Federal Ministry of Education and Research (BMBF, 01KU1403A EpiPD; 01EK1605A HitTau; 01DH18025 TauTherapy). D.H.G. is supported by 3UH3NS104095 and Tau Consortium. W.‐P.L. is supported by RF1‐AG074328, P30‐AG072979, U54‐AG052427, and U24‐AG041689. Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30 AG19610, and P30AG072980), the Arizona Department of Health Services (Contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (Contracts 4001, 0011, 05‐901, and 1001 to the Arizona Parkinson's Disease Consortium), and The Michael J. Fox Foundation for Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by National Institute on Aging (NIA) grants P50 AG016574, CurePSP Foundation, and support from Mayo Foundation. Relevant conflicts of interest/financial disclosures Funding agencies Investigators of the PSP Genetics Study Group are listed in the Appendix . ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Funding agencies: This work was supported by National Institutes of Health (NIH) 5UG3NS104095, the Rainwater Charitable Foundation, and CurePSP. H.W. and P.‐L.C. are supported by RF1‐AG074328, P30‐AG072979, U54‐AG052427, and U24‐AG041689. T.S.C. is supported by NIH K08AG065519 and the Larry L. Hillblom Foundation 2021‐A‐005‐SUP. Y.‐Q.S., A.T., and J.‐Y.T. are supported by RF1‐AG074328. K.F. was supported by CurePSP 685‐2023‐06‐Pathway and K01 AG070326. M.G. is supported by P30 AG066511. B.F.G. and K.L.N. are supported by P30 AG072976 and R01 AG080001. T.G.B. and G.E.S. are supported by U24 NS072026, P30 AG019610, P30AG072980, the State of Arizona, and The Michael J. Fox Foundation for Parkinson's Research. I.L. is supported by 2R01AG038791‐06A, U01NS100610, R25NS098999, U19 AG063911‐1, and 1R21NS114764‐01A1. O.A.R. is supported by U54 NS100693. D.G. is supported by P30AG062429. A.L.B. is supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. B.L.M. is supported by P01 AG019724, R01 AG057234, and P0544014. V.M.V.D. is supported by P01‐AG‐066597 and P01‐AG‐017586. H.R.M. is supported by CurePSP, PSPA, MRC, and The Michael J. Fox Foundation. R.D.S. is supported by CurePSP, PSPA, and Reta Lila Weston Trust. J.F.C. is supported by R01 AG054008, R01 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable Foundation/Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane Martin. A.M.G. is supported by the Tau Consortium and U54‐NS123746. Y.C. is supported by CIBERNED (CB06/05/0018‐ISCIII), Maria de Maeztu Excellence Center, CERCA Generalitat de Catalunya. Y.Y.L. is supported by U54‐AG052427 and U24‐AG041689. L.‐S.W. is supported by U01AG032984, U54AG052427, and U24AG041689. G.U.H. was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy‐ID 390857198); Deutsche Forschungsgemeinschaft (DFG, HO2402/18‐1 MSAomics); German Federal Ministry of Education and Research (BMBF, 01KU1403A EpiPD; 01EK1605A HitTau; 01DH18025 TauTherapy). D.H.G. is supported by 3UH3NS104095 and Tau Consortium. W.‐P.L. is supported by RF1‐AG074328, P30‐AG072979, U54‐AG052427, and U24‐AG041689. Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30 AG19610, and P30AG072980), the Arizona Department of Health Services (Contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (Contracts 4001, 0011, 05‐901, and 1001 to the Arizona Parkinson's Disease Consortium), and The Michael J. Fox Foundation for Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by National Institute on Aging (NIA) grants P50 AG016574, CurePSP Foundation, and support from Mayo Foundation. Relevant conflicts of interest/financial disclosures: L.M.‐P. received income from Biogen as a consultant in 2022. G.R. has been employed by Roche (Hoffmann‐La Roche, Basel, Switzerland) since 2021. Her affiliation while completing her contribution to this manuscript was German Center for Neurodegenerative Diseases (DZNE), Munich, Germany. T.G.B. is a consultant for Aprinoia Therapeutics and a scientific advisor and stock option holder for Vivid Genomics. H.R.M. is employed by University College London (UCL). In the last 12 months he reports paid consultancy from Roche, Aprinoia, AI Therapeutics, and Amylyx; and lecture fees/honoraria from BMJ, Kyowa Kirin, and the Movement Disorder Society. H.R.M. is a co‐applicant on a patent application related to C9ORF72: Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). G.C. is currently an employee of Regeneron Pharmaceuticals. A.M.G. serves on the scientific advisory board for Genentech and Muna Therapeutics. Investigators of the PSP Genetics Study Group are listed in the Appendix. |
ISSN: | 0885-3185 1531-8257 1531-8257 |
DOI: | 10.1002/mds.30150 |